Week in Review: Tasly Biopharma Completes Pre-IPO Round at $1.9 Billion Valuation

Deals and Financings   Tasly Biopharma of Shanghai raised $84.5 million in new capital and paid $48 million in stock to buy out China JV partner Transgene in a pre-IPO round that values Tasly at $1.9 billion; the company plans to IPO in Hong Kong ; GT Healthcare Capital of China and Sonder Capital of Silicon Valley closed a $26.6 million round in San Francico's Potero Medical, a medical device company; Beijing 's Hillhouse Capital and Sirona Capital of Australia co-led a $15 million Series C-1 funding for Antiva Bioscience, a South San Francisco biopharma; CC-Pharming of Beijing paid $4.7 million to in-license use of a plant-based technology developed by Texas ' iBio to develop and manufacture antibodies; Adlai Nortye Biopharma, a Hangzhou oncology in-licensing company, acquired global rights to a clinical-stage Novartis cancer drug, buparlisib; Haitong International of Hong Kong led the first close of a Series B round in Orig3n, a Boston genetics and regenerative medicine company; Germany 's Merck KGaA will market Xian Janssen's Inovokana®, a SGLT-2 treatment for type 2 diabetes, in China ; Zhejiang Dian Diagnostics formed a partnership with San Diego 's Agena Biosciences to promote Agena's MassARRAY® System in China ; IDS Medical Systems of Hong Kong partnered with WeDoctor, the Tencent online healthcare portal, to provide an online supply of medical devices; Trials and Approvals   Suzhou CStone Pharma was approved to start China trials of its PD-1 mAb, after a short, four-month review period; Adagene of Suzhou was approved to begin US trials of its lead product, ADG-106, in patients with advanced solid tumors and non-Hodgkin lymphoma. Stock Symbols: (SHA: 600535) (SHA: 600535) (P: TNG) (NYSE AMERICAN:IBIO) (NYSE: NVS) (F: MRK) (HK: 0700) Share this with colleagues: // //